Ingredients supplier Maypro has announced the launch of NeuroHD, a brain health ingredient composed of a non-synthetic histidine dipeptide complex derived naturally, which is marketed as a neuro-cognitive support supplement ingredient, produced by Maypro’s Tokyo-based partner, Tokai Bussan. It has been the subject of 8 human clinical trials which evidence that the complex helps to reduce markers of cognitive decline, preserves cognitive function, aids brain blood flow, reduces neuro-inflammation, enhances memory, helps reduce loss of memory, supports a healthy weight, and improves cardiovascular health, the company said.
 
The latest study on NeuroHD was published on Jan. 20 by University of Tokyo researcher Nobutaka Masuoka and colleagues in the journal Aging, and it was found that NeuroHD helped to prevent cognitive decline in people with mild cognitive impairment, which was attributed to the complex’s lowering of C-reactive protein and an enhancing of cerebral blood flow in healthy, elderly study participants.
 
Histidine dipeptide is a complex containing two naturally-occurring dipeptides, carnosine and anserine. Carnosine and anserine are evidenced to guard against neuro-inflammation, yield antioxidant properties, neutralize advanced glycation end-products, and are believed to have some anti-aging properties. NeuroHD is well-suited for beverage use in addition to conventional capsule formulations, and is available as both a carnosine-anserine version, or as NeuroHD-Marine, which is exclusively anserine.
 
“We are excited to be partnering with Tokai Bussan in offering this science-backed complex to the U.S. market,” Denis Alimonti, director of Proprietary Branded Ingredient Department, said. “Given the graying of the U.S. population, we believe that NeuroHD has immense potential, and we look forward to working with customers on unique formulations with this impressive ingredient complex.”